Matching articles for "Tivorbex"
Issue 1540 · February 12, 2018
Nonopioid Drugs for Pain

Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future issue.

Med Lett Drugs Ther. 2018 Feb 12; 60(1540):24-32
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future issue.
Issue 1490 · March 14, 2016
Low-Dose Meloxicam (Vivlodex) for Osteoarthritis Pain

The FDA has approved Vivlodex (Iroko), a low-dose formulation of the nonsteroidal anti-inflammatory drug meloxicam ( Mobic , and generics), for management of osteoarthritis pain. According to the manufacturer,…

Med Lett Drugs Ther. 2016 Mar 14; 58(1490):35-6
The FDA has approved Vivlodex (Iroko), a low-dose formulation of the nonsteroidal anti-inflammatory drug meloxicam ( Mobic , and generics), for management of osteoarthritis pain. According to the manufacturer, the new formulation aligns with stronger FDA warnings about the cardiovascular risks of NSAIDs and the recommendation to use the lowest possible doses of these drugs.
Issue 1447 · July 21, 2014 Free
In Brief: Low-Dose Indomethacin (Tivorbex) for Pain

The same pharmaceutical company (Iroko) that recently marketed low-dose diclofenac (Zorvolex) for treatment of mild to moderate acute pain 1 has now received approval from the FDA to market a low-dose oral…

Med Lett Drugs Ther. 2014 Jul 21; 56(1447):64
The same pharmaceutical company (Iroko) that recently marketed low-dose diclofenac (Zorvolex) for treatment of mild to moderate acute pain 1 has now received approval from the FDA to market a low-dose oral formulation of indomethacin (Tivorbex) for the same indication. Tivorbex is available in 20- and 40-mg capsules; conventional immediate-release indomethacin capsules contain 25 mg and 50 mg of the drug. The rationale for this new product is the same as the one offered for Zorvolex : the drug is formulated as submicron particles that increase surface area, leading to faster dissolution and absorption. According to the package insert, the time to reach peak serum concentrations (Tmax) was 1.67 hours with a 40-mg capsule of Tivorbex , compared to 2.02 hours with a standard 50-mg capsule of indomethacin. The problem with Tivorbex is the same as the problem with Zorvolex : there are no studies comparing its efficacy to that of standard doses of indomethacin or to any other NSAID. In addition, indomethacin is generally considered one of the most potent NSAIDs and one of those most likely to cause GI bleeding, increase cardiovascular risk, and damage the kidneys. There is no good reason to use indomethacin in any dosage for treatment of mild to moderate pain. Low-dose diclofenac (Zorvolex) for pain. Med Lett Drugs Ther 2014; 56:19. Download complete U.S. English article